Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded suppository containing mupirocin calcium, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing mupirocin are listed in ointment and cream forms. No finished mupirocin product of any kind is listed in suppository form.
Suppository bases differ, and the base used decides how USP <795> classifies the preparation for beyond-use dating. The date printed on the label is the one to follow.
Mupirocin is a topical antibiotic, commonly compounded into ointments, creams, nasal preparations and combination skin products.
Mupirocin is a topical antibiotic produced naturally by the bacterium Pseudomonas fluorescens. It blocks bacterial protein production by binding an enzyme called isoleucyl-tRNA synthetase, a target no other antibiotic class uses, and at the concentrations reached on the skin it kills susceptible bacteria rather than only slowing them. Manufactured products include mupirocin ointment 2%, FDA-approved for impetigo caused by susceptible Staphylococcus aureus and Streptococcus pyogenes, and mupirocin cream 2%, approved for secondarily infected traumatic skin lesions. A prescriber might order mupirocin compounded when a patient needs a vehicle free of polyethylene glycol or other excipients, a different base for a specific site, or a combination with another topical ingredient in one preparation. Compounded preparations are not FDA-approved and require a prescription.
Mupirocin has no FDA boxed warning. Do not use it if you are allergic to mupirocin or to polyethylene glycol, the base of the manufactured ointment. Keep it out of the eyes, where it causes burning and tearing. Severe allergic reactions including anaphylaxis, hives and swelling have been reported; get help right away for trouble breathing or facial swelling. Diarrhea during treatment or even more than two months after any antibiotic can signal C. difficile infection. Long courses can let resistant bacteria or fungi overgrow. The labels list no drug interactions. The skin ointment is not for the nose, eyes or IV sites. LactMed notes that less than 1% is absorbed through skin, so breastfeeding risk is low, and advises only a water-based cream or gel, not an ointment, on the breast; the ointment label says to wash a treated breast or nipple before nursing. Common side effects are burning, stinging, itching and rash. Talk to your prescriber or pharmacist about any side effect that worries you.
Mupirocin (pseudomonic acid A) reversibly and specifically inhibits bacterial isoleucyl-tRNA synthetase, halting protein synthesis; it is bactericidal at topical concentrations and shows no cross-resistance with other antibiotic classes, though high-level resistance arises through a plasmid-mediated alternative synthetase and is more frequent among MRSA (Khoshnood 2019). Systemic absorption through intact skin is minimal; absorbed drug is rapidly hydrolyzed to inactive monic acid and excreted renally, with an IV half-life of about 20 to 40 minutes. In a pharmacokinetic study cited in the Bactroban Nasal labeling, neonates and premature infants showed significant systemic absorption after intranasal use. Labeled indications: mupirocin ointment 2% for impetigo (S. aureus, S. pyogenes) and mupirocin cream 2% for secondarily infected traumatic skin lesions of limited size. The Khoshnood 2019 review describes wider use for staphylococcal skin and soft tissue infection and nasal decolonization where MRSA is endemic, with resistance rising where use is widespread. Dosing and duration are per prescriber. Monitor for local irritation, hypersensitivity and clinical failure; susceptibility testing is advised before treating MRSA. The polyethylene glycol ointment vehicle can be absorbed through open wounds and should be avoided where large amounts could be absorbed, especially with renal impairment. Mupirocin is not a controlled substance.
Wash your hands. If the suppository is soft, chill it in its wrapper in the refrigerator or under cool water for a few minutes, then unwrap it. For rectal use, coat the tip with a water-soluble lubricant (not petroleum jelly), lie on your side with your upper knee bent, and insert it pointed end first past the muscle at the opening. For vaginal use, lie on your back with knees bent and insert it as far as it comfortably goes, by finger or applicator; bedtime use limits leakage, and a panty liner protects clothing. Stay lying down about 15 minutes. Wash your hands.
Suppositories are nonaqueous, so under USP <795> they can carry a beyond-use date of up to 180 days at controlled room temperature or in the refrigerator when no other stability data apply. Storage depends on the base: fatty bases can soften at room temperature and may be labeled for the refrigerator, while polyethylene glycol bases usually do not need refrigeration. Keep them cool so they do not melt, and refrigerate them if your label says to.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Insert 1 unwrapped suppository
